Recommended Initial Insulin Regimen for Type 1 Diabetes
For newly diagnosed type 1 diabetes, initiate a basal-bolus regimen consisting of a long-acting basal insulin analog (insulin detemir or insulin glargine) combined with rapid-acting insulin analogs (aspart, lispro, or glulisine) administered before each meal.
Starting Regimen Structure
The optimal approach from diagnosis is 1:
- Basal insulin: Twice-daily insulin detemir OR once-daily insulin glargine
- Bolus insulin: Rapid-acting analog (aspart, lispro, or glulisine) before each meal
This multiple daily injection (MDI) regimen should be offered immediately at diagnosis, not as a later intensification 2, 1.
Initial Dosing Algorithm
Total daily dose calculation:
- Start with 0.5-0.6 units/kg/day for most patients 2
- If presenting with diabetic ketoacidosis (DKA), expect higher initial requirements of approximately 1.3-1.4 units/kg/day, which will decrease to around 0.8 units/kg/day within days 3
Dose distribution:
- 50% as basal insulin (divided if using detemir twice daily)
- 50% as prandial insulin (divided among three meals based on carbohydrate content)
Why This Regimen
The basal-bolus approach with analogs provides superior outcomes compared to older regimens 2, 4:
- Better glycemic control with lower HbA1c
- Reduced hypoglycemia risk, especially nocturnal episodes
- Lower intraindividual variability compared to NPH insulin
- Flexibility for varying meal times and carbohydrate intake
- Reduced weight gain compared to older insulins
Critical Implementation Points
Basal insulin selection:
- Long-acting analogs (detemir, glargine) are strongly preferred over NPH insulin 2, 4
- NPH has an undesirable peak effect, short duration, and high variability making it inappropriate for type 1 diabetes 4
- Insulin detemir typically requires twice-daily dosing; glargine is usually once daily
Prandial insulin selection:
- Any rapid-acting analog (aspart, lispro, glulisine) is preferred over regular human insulin 2
- Faster-acting insulin aspart offers even better postprandial coverage 2
- Regular human insulin has delayed onset and prolonged action, increasing hypoglycemia risk
Common Pitfalls to Avoid
Do not use premixed insulins - They lack the flexibility needed to address individual meal-to-meal variations and cannot adequately control postprandial glucose excursions 4
Do not use NPH as basal insulin - Its peak action, short duration, and high variability make it unsuitable for continuous basal coverage in type 1 diabetes 4
Do not delay intensive therapy - The basal-bolus regimen should be initiated at diagnosis, not after trying simpler regimens 1
Avoid therapeutic inertia - If the patient is already optimized on an alternative regimen, don't switch unnecessarily, but for new diagnoses, start with the optimal regimen 1
Patient Education Requirements
Concurrent with insulin initiation, patients require education on 2:
- Carbohydrate counting for prandial dose calculation
- Correction factors for premeal hyperglycemia
- Activity adjustments for exercise
- Frequent blood glucose monitoring (minimum 4-6 times daily)
- Hypoglycemia recognition and management
- Glucagon prescription for emergent hypoglycemia
Alternative Consideration
Continuous subcutaneous insulin infusion (insulin pump) should be considered for patients who 2:
- Fail to meet glycemic targets on MDI
- Experience frequent or severe hypoglycemia
- Have pronounced dawn phenomenon
- Express strong patient preference (if reimbursement available)
However, the initial regimen should still be the basal-bolus MDI approach described above, with pump therapy as an early transition option if indicated.